Whitehawk Therapeutics Buyback Yield % Related Terms
Whitehawk Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Whitehawk Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WHWK vs IMUX, TTRX, ALEC: Buyback Yield % Comparison
For the Biotechnology subindustry, Whitehawk Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Whitehawk Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Whitehawk Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Whitehawk Therapeutics (WHWK) has a Buyback Yield % of 0.00 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Whitehawk Therapeutics and its competitors. According to the industry distribution chart, Whitehawk Therapeutics ranks #999999 out of 744 companies in the Biotechnology industry.
Is Whitehawk Therapeutics' Buyback Yield % too high?
Whitehawk Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Whitehawk Therapeutics ranks #999999 out of 744 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Buyback Yield % compare to IMUX and TTRX?
According to the Biotechnology industry distribution chart, Whitehawk Therapeutics ranks #999999 out of 744 companies for Buyback Yield %. This places Whitehawk Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $4.19 — trading 1451.9% above its estimated fair value. The current Buyback Yield % is 0.00. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Buyback Yield % is 0.00 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?
Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued.
The current stock price of $4.19 is trading 1451.9% above its estimated GF Value™ of $0.27.
GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.
Key valuation signals for WHWK:
Buyback Yield %: 0.00
GF Value™: $0.27 vs. price of $4.19 (1451.9% above fair value)
No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score
Get the complete analysis for WHWK
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WHWK has been successfully added to your 
